Ketan K. Badani, MD

In considering patients’ busy lives, AI may help reduce the number of visits required to fully stage and grade cancers.

Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.

The poly-ICLC trial seeks to develop a delivery mechanism to prostate cancer through different biomarkers.